Trial Profile
A Prospective, Multicentric, Randomized, Double Blind, Parallel, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy along with Standard Supportive Care in Subjects of Acute Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sovateltide (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Pharmazz
- 11 Jan 2021 Results assessing the safety, tolerability and efficacy of sovateltide as an addition to standard of care in patients with acute cerebral ischemic stroke, published in the CNS Drugs
- 27 Apr 2020 Interim 30-day analysis published in the Pharmazz Media Release.
- 21 Feb 2020 Results presented at the International Stroke Conference 2020